Exagen Inc. (NYSE:XGN) – Investment analysts at Cantor Fitzgerald issued their FY2019 earnings estimates for Exagen in a research note issued to investors on Thursday, October 17th. Cantor Fitzgerald analyst C. Bijou expects that the company will post earnings of ($1.63) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $18.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Exagen’s FY2020 earnings at ($1.23) EPS.
Several other research firms have also weighed in on XGN. William Blair began coverage on shares of Exagen in a research note on Monday, October 14th. They issued an “outperform” rating on the stock. Cowen began coverage on shares of Exagen in a research note on Monday, October 14th. They issued an “outperform” rating and a $17.00 price objective on the stock.
In related news, major shareholder Bio-Exagen L.P. H.I.G. acquired 859,897 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were purchased at an average price of $17.24 per share, for a total transaction of $14,824,624.28.
Exagen Company Profile
Exagen Inc operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia.
Recommended Story: How to build a Fibonacci channel
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.